US 11401328
Antibodies binding to ILT4
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 11401328 (Antibodies binding to ILT4) held by Five Prime Therapeutics, Inc. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P